24/7 Market News Snapshot 25 February, 2025 – Silexion Therapeutics Corp Ordinary Shares (NASDAQ:SLXN)

February 25, 2025

DENVER, Colo., 25 February, 2025 (247marketnews.com) – (NASDAQ:SLXN) are discussed in this article.
Silexion Therapeutics Corp. (NASDAQ:SLXN), a clinical-stage biotechnology firm focused on developing RNA interference (RNAi) therapies for KRAS-driven cancers, is experiencing a notable surge in its stock price, which has increased to $1.103, representing a significant rise of 47.07% from its previous close of $0.750. This bullish momentum is indicative of growing investor interest, reflected in a trading volume of 4.09 million shares. Analysts anticipate that, if this upward trend persists, SLXN may reach new heights in the near future.

Further underscoring this momentum, Silexion has announced significant progress in its SIL-204 development program, notably in its innovative approach to treating pancreatic cancer. The company has successfully completed an initial study assessing SIL-204 in orthotopic pancreatic cancer models, marking an important milestone. This study is particularly groundbreaking as it evaluates SIL-204 administered subcutaneously, closely mimicking the complex tumor microenvironment and metastatic behavior inherent to pancreatic cancer.

Dr. Mitchell Shirvan, Chief Scientific Officer of Silexion, emphasized the significance of the study, which aims to establish the efficacy of SIL-204 in inhibiting primary tumor growth while also preventing metastasis to secondary organs. Chairman and CEO Ilan Hadar added to the sentiment, highlighting the excitement surrounding the implications of these findings.

Initial results from the study are expected to be released in March 2025 and are anticipated to play a critical role in shaping the strategic direction of Silexion’s development plans for SIL-204. As the company forges ahead with its research initiatives, it remains dedicated to advancing treatment options for patients suffering from challenging KRAS-driven cancers, aiming to redefine care in this difficult therapeutic area.

Related news for (SLXN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.